I am estimating they spent ~$14mil per year for R&D, Pre-Commercializatioon Exp & G&A Expense - that's 28mil over the past two years plus another 6 for the last 5 mos. The bulk of the deficit predates Covid. My point is that RVX is spent and without a revenue generating product they will need a major dilutive infusion to continue operations if this Covid trial fails.